MIF

Across TCGA pan-cancer cohorts, MIF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MIF data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MIF mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MIF expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where MIF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.457	0.837	.001	23	view →
CCRCC	DFS	Quartile	All	0.971	0.472	.017	12	view →
HNSC	DFS	Tertile	II,III,IV	0.559	0.744	.026	11	view →
GBM	DFS	Quartile	All	0.182	0.512	.008	10	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MIF–LUAD (OS)

Open the LUAD breakdown →